ClinicalTrials.gg
WithdrawnNCT04293172HESTIA5Updated Jul 15, 2020

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

A Phase 3 interventional study of Brilinta and Placebo in Sickle Cell Disease, sponsored by AstraZeneca. Withdrawn. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-07-15.

Primary conditionVaso-Occlusive CrisesRegistry: Anemia, Sickle CellReclassifiedWhy we changed it
Registry
Anemia, Sickle Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Vaso-Occlusive Crises
Why
  1. The study's title name Vaso-Occlusive Crises, a narrower term within Anemia, Sickle Cell.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study halted prematurely, prior to enrolment of first patient.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease

Read the detailed description
  • HESTIA5 will evaluate the efficacy, safety and tolerability of ticagrelor versus placebo in children with SICKLE CELL DISEASE during treatment for at least 12 months and up to a maximum of 24 months.
  • The target population are children (males and females) aged 6 months to \<18 years and body weight ≥6 kg diagnosed with homozygous sickle cell or sickle beta-zero-thalassaemia confirmed by high-performance liquid chromatography or hemoglobin electrophoresis. The aim is to randomise 20 patients in the age group 6 to \<24 months. At least 50 patients should be randomised in each of the age groups: ≥2 to \<12 years and ≥12 to \<18 years.
  • Prior to randomisation in this study, patients aged 6 to \<24 months will undergo a 14-day Run in period in which they will receive open-label ticagrelor twice a day for 14 days according to weight. Run-in period includes 4 visits, called R1, R2, R3 and R4. The run-In period is to ensure that the treatment is well-tolerated, and that the exposure is in line with model-based predictions following repeated twice a day dosing with ticagrelor in this age group. At the end of the Run-in period (Visit R4), the patient will take his/her final dose of open-label IP and await the independent Data Monitoring Committee chairman's evaluation of tolerability, safety and exposure before being eligible to enter the Screening period for randomisation. Patients who complete the Run-in period according to the protocol must also meet all the inclusion/exclusion criteria detailed in Protocol, to proceed to randomisation.
  • To be eligible for the study, patients must have experienced at least 2 VASO-OCCLUSIVE CRISES (defined as painful crisis and/or ACUTE CHEST SYNDROME) events in the past 12 months prior to Visit 1, (patients aged 2 to \<18 years) and prior to visit R1 (patients aged 6 to \<24 months) indicating that the severity of the patient's disease justifies preventive chronic long-term treatment. Even if painful VASO-OCCLUSIVE CRISES are uncommon in infants and become more frequent in older children, data show that symptoms like dactylitis precede more severe events and confirm that children who have early dactylitis are more likely to have severe events later in life.
  • Study participants should receive standard of care for SICKLE CELL DISEASE, adjusted to the individual patient at the discretion of the investigator, including routine health care screening examinations and immunizations to local guidelines and health care programmes. Study drug will be given on the background of standard treatments for SICKLE CELL DISEASE. Study participants are not withheld from any other treatments that may be used in SICKLE CELL DISEASE (eg., hydroxyurea) during the trial, which is important considering the use of a placebo control group. However, restrictions apply to some medications and interventions that may be necessary for the patient's health and well-being during the study.
  • Patients are to be followed until a common study end date (CSED) is reached defined as 12 months after the last patient is randomized. Treatment duration is at least 12 months for study participants, and patients will continue on treatment until 12 months after last randomized patient or up to a maximum of 24 months. The expected average follow-up is 18 months, assuming a uniformly distributed enrolment period of 12 months. Considering inclusion of patients with at least 2 VASO-OCCLUSIVE CRISES in the past year, this treatment duration is considered long enough to evaluate effects on VASO-OCCLUSIVE CRISES events as well as to capture safety and tolerability data supporting a potential future long term use of ticagrelor.
  • Due to ticagrelor mechanism of action and the potential to reduce symptoms caused by ischemia during a vaso-occlusion, a composite endpoint with painful crises and/or ACUTE CHEST SYNDROME has been selected for the primary endpoint. Painful crisis is the most common reason for emergency department visits for patients with SICKLE CELL DISEASE with a significant impact on young patients' lives, affecting them physically and emotionally. Secondary endpoints are included to broaden the understanding of effects in patients with SICKLE CELL DISEASE and to also assess potential benefits on symptomatic disease burden and health-related quality of life (HRQL).
  • Patients will be treated with 5, 10, 15, 30 and 45 mg twice a day or matching placebo, depending on body weight.
02

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Ticagrelor
  • Vaso-Occlusive Crises
  • Paediatric Patients
  • 6 Months to <18 Years
  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Platelet aggregation
  • Brillinta
  • Acute Chest Syndrome
  • painful crisis
03

In context

Vaso-Occlusive Crises Reclassified

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated prior to any study specific procedures not part of standard medical care (local regulations and international guidelines are to be followed in determining the assent/consent requirements for children).
  2. Children aged 6 months to \<18 years of age and body weight ≥6 kg diagnosed with HbSS or HbS/β0 as confirmed by high-performance liquid chromatography (HPLC) or electrophoresis.
  3. Have experienced at least 2 VASO-OCCLUSIVE CRISES (painful crisis and/or ACUTE CHEST SYNDROME) as judged by the Investigator in the past 12 months prior to Visit R1 (patients aged 6 to \<24 months) or Visit 1 (patients aged 2 to \<18 years). These VASO-OCCLUSIVE CRISES need to be documented in the patient's medical records or in other documents that can be reconciled.
  4. If aged 2 to ≤16 years, must have had a TCD within the past year prior to Visit 2. If this is not the case, a TCD examination must be done before randomisation.
  5. If aged ≥10 years, must have had an ophthalmological examination within the past year prior to Visit 1. If this is not the case, the patient must be examined by an ophthalmologist before proceeding in the study. If local guidelines dictate ophthalmological examination at younger ages, those local guidelines should be followed.
  6. If treated with hydroxyurea or L-glutamine, the weight-adjusted dose must be stable for 3 months before screening.
  7. Suitable venous access for the study-related blood sampling.
  8. Prior to dosing on day of randomisation (Visit 2), a negative urine (dipstick) pregnancy test performed at Enrolment (Visit 1) and at Visit 2 must be available for female patients of .
  9. Females of childbearing potential (after menarche) must not become pregnant during the study. Sexually active females must use a highly effective method of which results in a low failure rate (ie, less than 1% per year). If use of effective contraception cannot be secured in sexually active females, the patient cannot be included in this study.

Exclusion criteria

Exclusion Criteria:

  1. As judged by the Investigator, any evidence of unsuitability which in the Investigator's opinion makes it undesirable for the patient to participate in the study.
  2. History of (TIA) or cerebrovascular accident (ischaemic or haemorrhagic), severe head trauma, intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy.
  3. Findings on TCD: Current or previous values for time averaged mean of the maximum velocity (TAMMV) that are Conditional or Abnormal. Patients with Conditional TAMMV values or higher (≥153 cm/sec using TCD imaging technique [TCDi] which is corresponding to ≥170 cm/sec by the non-imaging technique). Both the middle cerebral artery and the internal carotid artery should be considered. Any other criteria that would locally be considered as TCD indications for chronic transfusion would also exclude the patient.
  4. Pathological finding on any other imaging assay indicating increased risk for intracerebral bleeding or thromboembolism.
  5. (INR) >1.4 or active pathological bleeding or increased risk of bleeding complications according to Investigator.
  6. \<6 g/dL from test performed at Visit R1 and Visit 1 (patients aged 6 to \<24 months) or at Enrolment (Visit 1) (patients aged 2 to \<18 years).
  7. \<100 × 109/L from test performed at Visit R1 and Visit 1 (patients aged 6 to \<24 months) or at Enrolment (Visit 1) (patients aged 2 to \<18 years).
  8. Undergoing treatment with chronic red blood cell transfusion therapy.
  9. Chronic use of NSAIDs defined as continuous intake >3 days per week that cannot be discontinued.
  10. Receiving chronic treatment with anticoagulants or antiplatelet drugs that cannot be discontinued.
  11. Moderate or severe hepatic impairment defined as laboratory values of (ALT) >2× (ULN), total >2×ULN (unless judged by the Investigator to be caused by haemolysis), albumin \<35 g/L (3.5 g/dL) and INR >1.4, or symptoms of liver disease (eg, ascites) from test performed at Visit R1 and Visit 1 (patients aged 6 to \<24 months) or at Enrolment (Visit 1) (patients aged 2 to \<18 years).
  12. Renal failure requiring dialysis.
  13. Patient considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second- or third-degree atrioventricular block) unless already treated with a permanent pacemaker.
  14. Concomitant oral or intravenous therapy with strong cytochrome P450 3A () inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers, which cannot be stopped at least 5 half-lives before randomisation.
  15. Active untreated malaria. Patients with suspected malaria at Visit R1 (patients aged 6 to \<24 months) or at Enrolment (Visit 1) (patients aged 2 to \<18 years) will be tested.
  16. Known or to ticagrelor.
  17. Patients who are currently pregnant or breastfeeding or planning to become pregnant during the study or have given birth less than 3 months prior to Enrolment (Visit 1).
  18. Concern for the inability of the patient or caregiver (defined as legally authorised representative) to comply with study procedures and/or follow-up.
  19. Previous randomisation in the present study or participation in any previous HESTIA study.
  20. Participation in another clinical study with an IP or device during the last 30 days preceding screening.
  21. Involvement of member of patient's family, or patient self, in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    The double-blinded study drug dose will be weight dependent.

    Drug: Brilinta

  • Placebo comparator
    Placebo

    The double-blinded study drug dose will be weight dependent

    Drug: Placebo

Interventions

  • Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days. The double-blind IP will be based on 5 weight bands: * 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day * \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day * \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day * \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day * \>48 kg: ticagrelor 45 mg or matching placebo, twice a day

  • DrugPlacebo

    Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days. The double-blind IP will be based on 5 weight bands: * 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day * \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day * \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day * \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day * \>48 kg: ticagrelor 45 mg or matching placebo, twice a day

06

What researchers measure

Primary outcomes

  1. Number of Vaso-Occlusive Crises

    Vaso-occlusive crises (VOC) defined as the composite of a painful crisis and/or an Acute Chest Syndrome (ACS) . Each component is defined as: A painful crisis is an onset or worsening of pain that lasts at least 2 hours, for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, parenteral NSAIDs, or other analgesics prescribed by a health care provider in a medical setting (such as a hospital, clinic or emergency room visit) or at home. An ACS is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray.

    Time frame: Up to end of study visit (12 to 24 months)

Secondary outcomes

  1. Number of Vaso-Occlusive Crises in patients aged 2 to <18 years

    Time frame: Up to end of study visit (12 to 24 months)

  2. Number of painful crises

    Time frame: Up to end of study visit (12 to 24 months)

  3. Number of Acute Chest Syndromes

    Time frame: Up to end of study visit (12 to 24 months)

  4. Duration of painful crises

    Time frame: Up to end of study visit (12 to 24 months)

  5. Number of Vaso-Occlusive Crises requiring hospitalisation or emergency department visits

    Time frame: Up to end of study visit (12 to 24 months)

  6. Number of days hospitalised for Vaso-Occlusive Crises

    Time frame: Up to end of study visit (12 to 24 months)

  7. Number of acute Sickle Cell Disease complications

    Time frame: Up to end of study visit (12 to 24 months)

  8. Number of days hospitalised for acute Sickle Cell Disease complications

    Time frame: Up to end of study visit (12 to 24 months)

  9. Number of sickle cell-related red blood cell (RBC) transfusions

    Time frame: Up to end of study visit (12 to 24 months)

  10. Health-related quality of life (HRQL)

    HRQL total score and by dimension using Paediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module; and Fatigue total score and by dimension using the PedsQL Multidimensional Fatigue Scale (age appropriate versions: 2 to 4 years; 5 to 7 years; 8 to 12 years; 13 to 18 years); HRQL total score and by dimension using the PedsQL Infant Scale (age appropriate versions: 1 to 12 months; 13 to 24 months)

    Time frame: At randomization, visit 9 (6 months), visit 15 (12 months), visit 21 (18 months) and End of Study visit (12 to 24 months).

  11. Absence from school or work due to Sickle Cell Disease

    Proportion of days of absence from school or work (only if going to school or work at randomisation)

    Time frame: Up to end of study visit (12 to 24 months)

  12. Intensity of pain during Vaso-Occlusive Crises in patients aged ≤4 years

    Intensity of worst pain daily during Vaso-Occlusive Crises - For patients aged ≤4 years, observer reported using the Face, Legs, Activity, Cry, Consolability (FLACC) scale

    Time frame: Up to end of study visit (12 to 24 months)

  13. Intensity of pain during Vaso-Occlusive Crises for patients aged 5 to <18 years

    Intensity of worst pain daily during Vaso-Occlusive Crises - For patients aged 5 to \<18 years, self-reported using the Faces Pain Scale - Revised (FPS-R)

    Time frame: Up to end of study visit (12 to 24 months)

  14. Type of analgesics (opioid and non-opioid) use

    Time frame: Up to end of study visit (12 to 24 months)

  15. Palatability and Swallowability

    For patients aged ≤4 years taking the tablet dispersed or whole, an observer assessment of palatability will be undertaken

    Time frame: Immediately after administration of IP at randomization and visit 9 (6 months)

  16. Palatability and Swallowabilty

    For patients aged ≥5 years taking the tablet dispersed or whole, palatability will be assessed and categorised using the Facial Hedonic Scale

    Time frame: Immediately after administration of IP at randomization and visit 9 (6 months)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2020; primary completion for Oct 2022, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Mar 3, 2020
StartEst.
Jun 30, 2020
Primary completionEst.
Oct 10, 2022
CompletionEst.
Oct 10, 2022
Last update
Jul 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04293172
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Jun 30, 2020 (estimated)
Primary completion
Oct 10, 2022 (estimated)
Completion
Oct 10, 2022 (estimated)
Last update
Jul 15, 2020

Study contacts

Anders Berggren, MD, PhD
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion